AstraZeneca : FDA Approves Truqap Combination For PTEN-Deficient Metastatic Prostate Cancer

(RTTNews) - AstraZeneca's (AZN,AZN.L,ZEG.DE,AZN.ST) Truqap (capivasertib), in combination with abiraterone and prednisone, has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or - https://www.nasdaq.com/articles/astrazeneca-fda-approves-truqap-combination-pten-deficient-metastatic-prostate-cancer